Fuguo Jiang

Fuguo Jiang

Auto-generated profile, based on publicly available information

Fuguo Jiang

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2017 in Annual Review of Biophysics
Verified
Journal Article
Closed access
FJFuguo Jiang
Fuguo Jiang
JDJennifer A. Doudna
Jennifer A. Doudna
Many bacterial clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated (Cas) systems employ the dual RNA–guided DNA endonuclease Cas9 to defend against invading phages and conjugative plasmids by introducing site-specific double-stranded breaks in target DNA. Target recognition strictly requires the presence of a short protospacer adjacent motif (PAM) flanking the target site, and subsequent R-loop formation and strand scission are driven by complementary base pairing between the guide RNA and target DNA, Cas9–DNA interactions, and associated conformational changes. The use of CRISPR–Cas9 as an RNA-programmable DNA targeting and editing platform is simplified by a synthetic single-guide RNA (sgRNA) mimicking the natural dual trans-activating CRISPR RNA (tracrRNA)–CRISPR RNA (crRNA) structure. This review aims to provide an in-depth mechanistic and structural understanding of Cas9-mediated RNA-guided DNA targeting and cleavage. Molecular insights from biochemical and structural studies provide a framework for rational engineering aimed at altering catalytic function, guide RNA specificity, and PAM requirements and reducing off-target activity for the development of Cas9-based therapies against genetic diseases.

1 February 2019 in Molecular Cell
Verified
Journal Article
Closed access
FJFuguo Jiang
Fuguo Jiang
JLJun-Jie Liu
Jun-Jie Liu
BOBeatriz A. Osuna
Beatriz A. Osuna
Michael XuMichael Xu
Michael Xu
JBJoel D. Berry
Joel D. Berry
JDJennifer A. Doudna
Jennifer A. Doudna

9 June 2020 in The Analyst
Verified
Journal Article
Closed access
PDF file
JCJuhong Chen
Juhong Chen
FJFuguo Jiang
Fuguo Jiang
CHChao-Wei Huang
Chao-Wei Huang
LLLiwei Lin
Liwei Lin
A new method based on the technique of CRISPR-Cas12a is developed to accomplish a bacterial antibiotic susceptibility test (AST) within one hour with good accuracy.

3 September 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
FJFuguo Jiang
Fuguo Jiang
JLJun-Jie Liu
Jun-Jie Liu
BOBeatriz A. Osuna
Beatriz A. Osuna
Michael XuMichael Xu
Michael Xu
JBJoel D. Berry
Joel D. Berry
JDJennifer A. Doudna
Jennifer A. Doudna
SUMMARY: CRISPR–Cas immune systems utilize RNA-guided nucleases to protect bacteria from bacteriophage infection. Bacteriophages have in turn evolved inhibitory ‘anti-CRISPR’ (Acr) proteins, including six inhibitors (AcrIIA1-6) that can block DNA cutting and genome editing by type II-A CRISPR-Cas9 enzymes. We show here that AcrIIA2 and its homologue, AcrIIA2b, prevent Cas9 binding to DNA by occluding protein residues required for DNA binding. Cryo-EM-determined structures of AcrIIA2 or AcrIIA2b bound to S. pyogenes Cas9 reveal a mode of competitive inhibition of DNA binding that is distinct from other known Acrs. Differences in the temperature dependence of Cas9 inhibition by AcrIIA2 and AcrIIA2b arise from differences in both inhibitor structure and the local inhibitor-binding environment on Cas9. These findings expand the natural toolbox for regulating CRISPR-Cas9 genome editing temporally, spatially and conditionally.